New Delhi, February 10th, 2026 - ErlySign, the innovative biotech company from Nagpur that is transforming early cancer detection with non-invasive diagnostics, has been granted the US Food and Drug Administration (FDA) Breakthrough Device Designation for its saliva-based oral cancer early detection kit. The designation marks a significant global regulatory milestone for the company and underscores the potential of
Read More
